<DOC>
	<DOCNO>NCT01210768</DOCNO>
	<brief_summary>Primary objective : - To evaluate disease-free survival ( DFS ) two randomized arm therapy LC vs. EC chemo-naive Her2-patients stage I II breast cancer Secondary objective : - To assess overall survival ( OS ) - To establish safety profile assess toxicity tolerability - To assess quality life ( QoL ) - To evaluate survival correlation biomarkers expression .</brief_summary>
	<brief_title>A Study Pegylated Liposomal Doxorubicin Cyclophosphamide Her2-negative Stage I II Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>histologically confirm invasive , noninflammatory , breast adenocarcinoma stage I II ( N0 , T must &gt; 1cm ) disease Her2negative fluorescence situ hybridization ( FISH ) study performance status ECOG 0 , 1 female , age 20 70 year life expectancy least one year ability understand willingness sign write informed consent document Her2 3+ overexpression immunohistochemistry ( IHC ) , Her2 amplification fluorescence situ hybridization ( FISH ) study previous current systemic malignancy exception curatively treat nonmelanoma skin cancer cervical carcinoma situ , unless diseasefree interval least 5 year Patients receive prior chemotherapy inadequate hematological function define absolute neutrophil count ( ANC ) less 1,500/mm3 , platelet le 100,000/mm3 inadequate hepatic function define : serum bilirubin great 1.5 time upper limit normal range ( ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULN inadequate renal function define serum creatinine great 1.5 time ULN leave ventricular ejection fraction ( LVEF ) &lt; 50 % confirm multiplegated acquisition ( MUGA ) scan echocardiogram concomitant illness might aggregate chemotherapy interfere study assessment . For example , active , non control infection ( hepatitis B hepatitis C , HIV , infectious tuberculosis ) active , noncontrolled disease congestive heart failure , ischemic heart disease , uncontrolled hypertension arrhythmia , unstable diabetes mellitus , active peptic ulcer patient presence liver cirrhosis HBV/HCV carrier participation another clinical trial investigational drug within 30 day prior entry pregnant breast feed woman fertile woman childbearing potential unless use reliable appropriate contraceptive method throughout treatment period three month follow cessation treatment</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>Adjuvant Chemotherapy</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>